South Side-Based Knopp Lands $345M Deal for Lou Gehrig's Disease Drug

By Stouffer, Rick | Tribune-Review/Pittsburgh Tribune-Review, August 18, 2010 | Go to article overview
Save to active project

South Side-Based Knopp Lands $345M Deal for Lou Gehrig's Disease Drug

Stouffer, Rick, Tribune-Review/Pittsburgh Tribune-Review

A Pittsburgh research company said Wednesday it signed a deal potentially worth $345 million for final-stage development and commercialization of its treatment for Lou Gehrig's disease and possibly other degenerative nerve disorders.

Knopp Neurosciences Inc., on the South Side, announced the deal with Biogen Idec Inc., of Weston, Mass., on its new drug dexpramipexole, also known as KNS-760704, for treating amyotrophic lateral sclerosis, or ALS.

Some longtime investors in the 6-year-old Knopp compared its breakthrough research to another discovery made locally 55 years ago concerning another debilitating disease: Jonas Salk's discovery of a polio vaccine.

"This is the first drug ever to show the ability to slow the progression of ALS, to slow the rate of functional loss, potentially allowing the patient to walk, talk, eat and breathe better and longer," said CEO Michael Bozik at a news conference Downtown.

The deal is the latest in a series of significant investment deals won by Pittsburgh technology companies.

ALS causes progressive weakness in a patient due to the degeneration of nerve cells that control a body's voluntary muscles. "It's a progressive paralysis of the body while a person's mind stays intact," Bozik said.

ALS is always fatal, and patients generally die within two years of definitive diagnosis, but the Knopp drug slows the course of the disease by as much as 50 percent, Bozik said.

The drug penetrates a patient's nervous system and promotes energy production in nerve cells which, when stressed by ALS, require a great deal of energy, said Tom Petzinger, Knopp's executive vice president of business development and public affairs.

Petzinger is a founder of Pittsburgh life sciences company incubator Launchcyte LLC, which helped create and invested in Knopp.

"In the 31 counties of Western Pennsylvania, we generally work with 300 ALS patients and their families," said Michael Bernarding, executive director of the ALS Association of Western Pennsylvania, who spoke at the news conference.

Bernarding called the Knopp drug "exciting," saying that while ALS has been diagnosed in patients for 200 years, there is just one drug approved by the Food and Drug Administration for treating ALS, a drug Bernarding called "not very effective."

Nationwide, 20,000 to 30,000 people suffer from ALS, with about 5,000 diagnosed annually, Bernarding said.

Under terms of the agreement, Biogen will lead development of the drug and its potential commercialization worldwide, while Knopp will provide development support and conduct commercialization activities under Biogen's direction.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

South Side-Based Knopp Lands $345M Deal for Lou Gehrig's Disease Drug


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?